FindTrial
Sign In

Vigil™

BIOLOGICAL3 trials

Sponsors

Gradalis, Inc.

Conditions

Advanced Non-small Cell Lung CancerEwings SarcomaLiver CancerLung NeoplasmsMetastatic Non-small Cell Lung CancerNon Small Cell Lung CancerOvarian Cancer

Phase 1

Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
CompletedNCT01061840
Gradalis, Inc.Ewings Sarcoma, Liver Cancer, Non Small Cell Lung Cancer
Start: 2009-12-31End: 2019-01-31Updated: 2022-03-15

Phase 2

A Trial of FANG™ Vaccine for Participants With Ovarian Cancer
CompletedNCT01309230
Gradalis, Inc.Ovarian Cancer
Start: 2011-03-08End: 2022-02-02Updated: 2025-06-08
Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
WithdrawnNCT02639234
Gradalis, Inc.Advanced Non-small Cell Lung Cancer, Lung Neoplasms, Metastatic Non-small Cell Lung Cancer
Start: 2016-03-31End: 2017-03-31Updated: 2017-07-31

Related Papers

New advances in cancer therapy targeting TGF-β signaling pathways
Molecular Therapy — Oncolytics2023-12-0127 citations
Long-term follow-up of DNA engineered bi-shRNA furin GMCSF plasmid/autologous tumor induced immune response in patients with advanced solid tumors (phase I trial).
Journal of Clinical Oncology2017-03-01
Pilot trial of vigil immunotherapy in Ewing’s sarcoma.
Journal of Clinical Oncology2015-05-204 citations
Survival effect of bi-shRNA<sup>furin</sup>/GMCSF DNA-based immunotherapy (FANG) in 123 advanced cancer patients to α-interferon-ELISPTOT response.
Journal of Clinical Oncology2014-05-202 citations